Home / World Marketplace / Global Corporate Affairs / Archive by category Survey and Research (Page 3)

Archive by category Survey and Research

New report from Meltwater and We. Communications reveals 90% of PR teams are integrating generative AI into their workflows

SAN FRANCISCO, Jan. 14, 2026 (Korea Bizwire) – Meltwater, a global leader in media, social, and consumer intelligence, in partnership with We. Communications, released its first annual State of PR Report, based on insights from more than 1,100 PR and communications professionals worldwide. The report highlights how PR teams are navigating rising expectations, evolving measurement demands, and [...]

Bitget’s 2025 Review: UEX Leads the Convergence of Crypto and Traditional Markets

VICTORIA, Seychelles, Jan. 14, 2026 (Korea Bizwire) – Bitget, the world’s largest Universal Exchange (UEX), has published its year-in-review covering its Universal Exchange (UEX) model expansion across crypto, onchain markets, and tokenized traditional assets under a single, unified trading experience in 2025. According to CoinGlass’ 2025 Crypto Derivatives Market Annual Report, Bitget ranked fourth in 2025 by derivatives [...]

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis (IPF) Ingelheim, Germany, 13 January 2026 – Boehringer Ingelheim today announced the start of a Phase IIa clinical trial [...]

Payment Outages Threaten $44.4 Billion in U.S. Retail & Hospitality Sales Annually

New Study Reveals U.S. Businesses Average Over 5 Major Outages Annually, with 63% Occurring During Critical Peak Trading Times Philadelphia, PA and Boston, MA, Jan. 12, 2026 (Korea Bizwire) – A new study released today reveals that payment system failures are putting $44.4 billion in U.S. retail and hospitality sales at risk each year, underscoring how quickly [...]

Zoom Opens Nominations for First U.S. Solopreneur 50 List, Recognizing AI-First Solo Business Leaders

SAN JOSE, Calif., Jan. 08, 2026 (Korea Bizwire) – Today, Zoom opens nominations for its Zoom Solopreneur 50 List (ZSP50), a first-of-its-kind recognition and grant program celebrating the individuals who are redefining entrepreneurship by building and growing businesses on their own. Nominations are open until 5 p.m. ET on February 13, 2026. Individuals can nominate themselves or others [...]

[CORRECTING and REPLACING] BitMEX Report Finds Crypto Perpetuals Enter Post-Yield Era

State of Crypto Perpetual Swaps 2025 details market stress, trust gaps and new derivatives trends In a release issued under the same headline earlier today by BitMEX, please note that the link to the blog in the ninth paragraph has changed. The corrected release follows: VICTORIA, Seychelles, Jan. 08, 2026 (Korea Bizwire) – BitMEX, one of [...]

BitMEX Report Finds Crypto Perpetuals Enter Post-Yield Era

State of Crypto Perpetual Swaps 2025 details market stress, trust gaps and new derivatives trends VICTORIA, Seychelles, Jan. 08, 2026 (Korea Bizwire) – BitMEX, one of the safest exchanges, today released its end-of-year research report, “State of Crypto Perpetual Swaps 2025,” outlining five core insights that defined a turbulent year for the global crypto derivatives market. [...]

Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China

Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre for Drug Evaluation (CDE) and it is now under review BOSTON, Jan. 07, 2026 (Korea Bizwire) – Curium Shanghai Pharmaceuticals Co., Ltd. (科锐霖（上海）医药有限公司), has had its Investigational New Drug (IND) application [...]

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 status Late-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January [...]

Block Scholes Report Highlights Growth of Tokenized Stocks, Citing Bitget as a Key Market Driver

VICTORIA, Seychelles, Jan. 06, 2026 (Korea Bizwire) – Bitget, the world’s largest Universal Exchange (UEX), has been featured in a newly released report by Block Scholes, a leading digital asset analytics and research firm, examining the rapid growth of tokenized stocks and the evolving role of exchanges in bridging traditional and on-chain markets. According to the Block [...]